PE20061193A1 - DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 - Google Patents
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38Info
- Publication number
- PE20061193A1 PE20061193A1 PE2006000331A PE2006000331A PE20061193A1 PE 20061193 A1 PE20061193 A1 PE 20061193A1 PE 2006000331 A PE2006000331 A PE 2006000331A PE 2006000331 A PE2006000331 A PE 2006000331A PE 20061193 A1 PE20061193 A1 PE 20061193A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrimidin
- piperidinyl
- amino
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULAS I Y II DONDE G1 Y G2 SON CADA UNO N; G3 ES NH; G4 ES N; R1 ES CICLOPROPILMETIL-CARBAMIL, N-(4-FLUOROFENIL)-CARBAMIL, 3-TIOFENOCARBOXAMIDA, ENTRE OTROS; R1' ES HALOGENO, ALQUILO C1-C4, CIANO, NITRO, ENTRE OTROS; X ES 4-AMINO-PIPERIDINIL, 2-AMINOETIL-METILAMINO, 4-PIPERIDINILAMINO, ENTRE OTROS; R3 ES ALQUILO C1-C10, CICLOALQUILO C3-C7, ARILO, ARIL-ALQUILO C1-C10, ENTRE OTROS; g ES 0-4. SON COMPUESTOS PREFERIDOS: 3-[2-(4-AMINO-1-PIPERIDINIL)-8-(2,6-DIFLUOROFENIL)-7-OXO-5,6,,7,8,TETRAHIDRIPIRIMIDO[4,5-d]PIRIMIDIN-4-IL]-N-CICLOBUTIL-4-METILBENZAMIDA; 3-[2-(4-AMINO-1-PIPERIDINIL)-8-(2,6-DIFLUOROFENIL)-7-OXO-5,6,7,8-TETRAHIDROPIRIMIDO[4,5-d]PIRIMIDIN-4-IL]-N-[2-(4-FLUOROFENIL)ETIL]-4-METILBENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CITOQUINAS PROINFLAMATORIAS TALES COMO IL-1, IL-6, IL-8 Y TNF UTILES EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES TALES COMO OSTEOARTRITIS, ESCLEROSIS MULTIPLE, CHOQUE SEPTICO, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66534705P | 2005-03-25 | 2005-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061193A1 true PE20061193A1 (es) | 2006-12-02 |
Family
ID=37053936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010000198A PE20100741A1 (es) | 2005-03-25 | 2006-03-23 | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
PE2006000331A PE20061193A1 (es) | 2005-03-25 | 2006-03-23 | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010000198A PE20100741A1 (es) | 2005-03-25 | 2006-03-23 | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
Country Status (23)
Country | Link |
---|---|
US (4) | US20090239846A1 (es) |
EP (1) | EP1866311A4 (es) |
JP (1) | JP2008535820A (es) |
KR (1) | KR20080005223A (es) |
CN (1) | CN101184758B (es) |
AP (1) | AP2281A (es) |
AR (1) | AR053450A1 (es) |
AU (1) | AU2006229967B2 (es) |
BR (1) | BRPI0609579A2 (es) |
CA (1) | CA2602546A1 (es) |
EA (1) | EA200702074A1 (es) |
IL (1) | IL185915A0 (es) |
MA (1) | MA29340B1 (es) |
MX (1) | MX2007011883A (es) |
NO (1) | NO20075273L (es) |
NZ (1) | NZ561438A (es) |
PE (2) | PE20100741A1 (es) |
SG (1) | SG166100A1 (es) |
TW (1) | TW200724142A (es) |
UA (1) | UA95230C2 (es) |
UY (1) | UY29439A1 (es) |
WO (1) | WO2006104889A2 (es) |
ZA (1) | ZA200707798B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
DK1333833T3 (da) | 2000-10-23 | 2011-12-12 | Glaxosmithkline Llc | Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme |
RU2309951C2 (ru) | 2002-02-12 | 2007-11-10 | Смитклайн Бичем Корпорейшн | Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение |
US7629350B2 (en) * | 2002-04-19 | 2009-12-08 | Smithkline Beecham Corporation | Compounds |
EA200702073A1 (ru) * | 2005-03-25 | 2008-12-30 | Глэксо Груп Лимитед | Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных |
UY29439A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
JP2008535822A (ja) * | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
MY145343A (en) | 2005-03-25 | 2012-01-31 | Glaxo Group Ltd | Novel compounds |
WO2007147104A2 (en) * | 2006-06-16 | 2007-12-21 | Glaxo Group Limited | Novel compounds |
EP2032142A4 (en) * | 2006-06-16 | 2010-07-21 | Glaxo Group Ltd | NOVEL CONNECTIONS |
US20100144755A1 (en) * | 2006-06-16 | 2010-06-10 | Glaxo Group Limited | Novel Compounds |
AU2007346136B2 (en) * | 2007-02-09 | 2012-10-25 | Corteva Agriscience Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
WO2009152356A2 (en) * | 2008-06-11 | 2009-12-17 | Irm Llc | Compounds and compositions useful for the treatment of malaria |
CN103827118B (zh) * | 2011-07-27 | 2016-03-09 | 葛兰素集团有限公司 | 双环嘧啶酮化合物 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
UY37918A (es) | 2017-10-05 | 2019-04-30 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd |
CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN113750095B (zh) * | 2021-03-10 | 2023-07-04 | 中国医学科学院医药生物技术研究所 | 含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA966134A (en) | 1972-05-05 | 1975-04-15 | Haydn W.R. Williams | 1,8-naphthyridine compounds |
ZA803539B (en) | 1979-06-14 | 1982-01-27 | Wellcome Found | Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine |
GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
US4353656A (en) | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
WO1983002613A1 (en) | 1981-07-20 | 1983-08-04 | Sallmann, Alfred | Trisubstituted oxazo compounds |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GR79615B (es) | 1982-10-08 | 1984-10-31 | Glaxo Group Ltd | |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
JPS60226882A (ja) | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
US4560691A (en) | 1984-07-13 | 1985-12-24 | Sterling Drug Inc. | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation |
DK163640C (da) | 1985-07-30 | 1992-08-17 | Glaxo Group Ltd | Apparat til administrering af medikamenter |
AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
JPH01261306A (ja) | 1988-04-13 | 1989-10-18 | Nippon Kayaku Co Ltd | 2−アルキルチオ−4−アミノピリミジン誘導体を有効成分とする開花促進剤 |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
IE913473A1 (en) | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
JPH06502178A (ja) | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
DE4131029A1 (de) | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
US5466692A (en) | 1993-03-24 | 1995-11-14 | American Home Products Corporation | Substituted pyridopyrimidines and antihypertensives |
US5426110A (en) | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5547954A (en) | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
ATE191470T1 (de) | 1994-06-15 | 2000-04-15 | Wellcome Found | Enzymhemmer |
US5817670A (en) | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
JPH11501892A (ja) | 1995-03-10 | 1999-02-16 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | エアロゾルバルブ |
US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5760220A (en) | 1995-06-07 | 1998-06-02 | American Home Products Corporation | Process for preparation of biphenyl derivatives |
US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
CA2250943A1 (en) | 1996-04-12 | 1997-10-23 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
US6875769B2 (en) | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
AU709203B2 (en) | 1996-08-06 | 1999-08-26 | Pfizer Inc. | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
EA200000840A1 (ru) | 1998-02-17 | 2001-02-26 | Туларик, Инк. | Антивирусные производные пиримидина |
JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
US6248225B1 (en) * | 1998-05-26 | 2001-06-19 | Ppg Industries Ohio, Inc. | Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition |
KR20010043829A (ko) | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘 |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
EP1086085A1 (en) | 1998-06-12 | 2001-03-28 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
CN1158266C (zh) | 1998-10-01 | 2004-07-21 | 阿斯特拉曾尼卡有限公司 | 化合物 |
WO2000023444A1 (en) | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
CN1353717A (zh) | 1999-05-04 | 2002-06-12 | 莱加制药公司 | 四环黄体酮受体调节剂化合物及其方法 |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
AU7491400A (en) | 1999-09-17 | 2001-04-17 | Abbott Gmbh & Co. Kg | Kinase inhibitors as therapeutic agents |
AU2576501A (en) | 1999-12-08 | 2001-06-18 | Advanced Medicine, Inc. | Protein kinase inhibitors |
US6632666B2 (en) | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
SK10632002A3 (sk) | 2000-01-25 | 2003-06-03 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidín-2,7-diamínové inhibítory kinázy |
CN1433417A (zh) | 2000-01-27 | 2003-07-30 | 沃尼尔·朗伯公司 | 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物 |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
MXPA02008535A (es) | 2000-03-06 | 2002-12-13 | Warner Lambert Co | Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa. |
AU2001283004A1 (en) * | 2000-07-24 | 2002-02-05 | Vivcom, Inc. | System and method for indexing, searching, identifying, and editing portions of electronic multimedia files |
CA2423251A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
AU2002248269A1 (en) | 2000-10-19 | 2002-08-12 | Smithkline Beecham Corporation | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
DK1333833T3 (da) | 2000-10-23 | 2011-12-12 | Glaxosmithkline Llc | Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme |
WO2002058695A1 (en) | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
WO2003010143A1 (en) | 2001-07-26 | 2003-02-06 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
JP4178783B2 (ja) | 2001-10-19 | 2008-11-12 | 三菱化学株式会社 | 光学記録媒体 |
US7019002B2 (en) | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
JP2005519897A (ja) | 2002-01-14 | 2005-07-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、それを含む医薬製剤及びその使用 |
JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
CA2473026C (en) * | 2002-01-22 | 2011-05-03 | Warner-Lambert Company Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
EP1490062B1 (en) | 2002-03-26 | 2007-12-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
JP4570878B2 (ja) | 2002-04-11 | 2010-10-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体モジュレーターとしての1H−ベンゾ[f]インダゾール−5−イル誘導体 |
AU2003232071A1 (en) | 2002-05-06 | 2003-11-17 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
ES2518940T3 (es) | 2002-07-08 | 2014-11-06 | Pfizer Products Inc. | Moduladores del receptor de glucocorticoides |
EP1575502B1 (en) | 2002-07-18 | 2010-01-20 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6858627B2 (en) | 2002-08-21 | 2005-02-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
AU2003291310A1 (en) | 2002-11-06 | 2004-06-03 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換6,6−ヘテロ二環式誘導体 |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
EP1596860A4 (en) | 2003-02-14 | 2009-05-27 | Smithkline Beecham Corp | NEW CONNECTIONS |
US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
JP2007501854A (ja) | 2003-05-27 | 2007-02-01 | ファイザー・プロダクツ・インク | 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド[3,4−d]ピリミジン類 |
TWI220897B (en) * | 2003-07-22 | 2004-09-11 | Benq Corp | Recording media feeding system and method |
AR045445A1 (es) | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
WO2006039469A1 (en) * | 2004-09-29 | 2006-04-13 | Graphic Packaging International, Inc | Carton with dispenser having access features |
JP5111113B2 (ja) * | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
EA200702073A1 (ru) | 2005-03-25 | 2008-12-30 | Глэксо Груп Лимитед | Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных |
MY145343A (en) * | 2005-03-25 | 2012-01-31 | Glaxo Group Ltd | Novel compounds |
JP2008535822A (ja) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
UY29439A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
-
2006
- 2006-03-23 UY UY29439A patent/UY29439A1/es unknown
- 2006-03-23 PE PE2010000198A patent/PE20100741A1/es not_active Application Discontinuation
- 2006-03-23 AR ARP060101148A patent/AR053450A1/es not_active Application Discontinuation
- 2006-03-23 TW TW095109982A patent/TW200724142A/zh unknown
- 2006-03-23 PE PE2006000331A patent/PE20061193A1/es not_active Application Discontinuation
- 2006-03-24 US US11/908,435 patent/US20090239846A1/en not_active Abandoned
- 2006-03-24 AP AP2007004171A patent/AP2281A/xx active
- 2006-03-24 EP EP06748656A patent/EP1866311A4/en not_active Withdrawn
- 2006-03-24 JP JP2008503226A patent/JP2008535820A/ja active Pending
- 2006-03-24 US US11/389,112 patent/US7674789B2/en not_active Expired - Fee Related
- 2006-03-24 NZ NZ561438A patent/NZ561438A/en not_active IP Right Cessation
- 2006-03-24 KR KR1020077024433A patent/KR20080005223A/ko not_active Application Discontinuation
- 2006-03-24 AU AU2006229967A patent/AU2006229967B2/en not_active Ceased
- 2006-03-24 CA CA002602546A patent/CA2602546A1/en not_active Abandoned
- 2006-03-24 CN CN2006800183985A patent/CN101184758B/zh not_active Expired - Fee Related
- 2006-03-24 WO PCT/US2006/010792 patent/WO2006104889A2/en active Application Filing
- 2006-03-24 MX MX2007011883A patent/MX2007011883A/es active IP Right Grant
- 2006-03-24 UA UAA200710644A patent/UA95230C2/ru unknown
- 2006-03-24 EA EA200702074A patent/EA200702074A1/ru unknown
- 2006-03-24 SG SG201006926-8A patent/SG166100A1/en unknown
- 2006-03-24 BR BRPI0609579-8A patent/BRPI0609579A2/pt not_active IP Right Cessation
-
2007
- 2007-09-11 IL IL185915A patent/IL185915A0/en unknown
- 2007-09-12 ZA ZA200707798A patent/ZA200707798B/xx unknown
- 2007-09-24 MA MA30236A patent/MA29340B1/fr unknown
- 2007-10-15 NO NO20075273A patent/NO20075273L/no not_active Application Discontinuation
-
2009
- 2009-11-16 US US12/618,933 patent/US20100093766A1/en not_active Abandoned
- 2009-11-16 US US12/618,927 patent/US20100093765A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP2281A (en) | 2011-10-31 |
WO2006104889A2 (en) | 2006-10-05 |
US20100093765A1 (en) | 2010-04-15 |
AR053450A1 (es) | 2007-05-09 |
SG166100A1 (en) | 2010-11-29 |
EP1866311A2 (en) | 2007-12-19 |
JP2008535820A (ja) | 2008-09-04 |
NO20075273L (no) | 2007-12-12 |
UA95230C2 (ru) | 2011-07-25 |
US20100093766A1 (en) | 2010-04-15 |
BRPI0609579A2 (pt) | 2010-04-20 |
MX2007011883A (es) | 2007-11-13 |
CA2602546A1 (en) | 2006-10-05 |
UY29439A1 (es) | 2006-10-02 |
MA29340B1 (fr) | 2008-03-03 |
WO2006104889A3 (en) | 2007-04-12 |
IL185915A0 (en) | 2008-01-06 |
CN101184758B (zh) | 2012-05-02 |
TW200724142A (en) | 2007-07-01 |
CN101184758A (zh) | 2008-05-21 |
PE20100741A1 (es) | 2010-11-25 |
AU2006229967B2 (en) | 2012-02-09 |
KR20080005223A (ko) | 2008-01-10 |
US20090239846A1 (en) | 2009-09-24 |
US7674789B2 (en) | 2010-03-09 |
EA200702074A1 (ru) | 2008-02-28 |
EP1866311A4 (en) | 2010-03-31 |
US20060235030A1 (en) | 2006-10-19 |
AU2006229967A1 (en) | 2006-10-05 |
ZA200707798B (en) | 2009-08-26 |
AP2007004171A0 (en) | 2007-10-31 |
NZ561438A (en) | 2011-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061193A1 (es) | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 | |
PE20081370A1 (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
PE20100737A1 (es) | Nuevos compuestos | |
PE20081581A1 (es) | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA | |
PE20081346A1 (es) | Derivados de espiroindolinona como antagonistas de mdm2 | |
CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
PE20040168A1 (es) | Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas | |
PE20140407A1 (es) | Nuevos compuestos triciclicos | |
PE20090279A1 (es) | Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 | |
PE20060299A1 (es) | DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA | |
MXPA04003474A (es) | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a. | |
RU2006137716A (ru) | Ингибиторы гистондеацетилазы | |
PE20121150A1 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
PE20030847A1 (es) | Aza-arilpiperazinas como ligandos del receptor 5ht2 | |
CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
JP2007515405A5 (es) | ||
EA200800992A1 (ru) | 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения | |
TW200745130A (en) | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | |
PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
AP1789A (en) | Tropane derivatives useful in therapy. | |
JP2014531449A5 (es) | ||
AU2006294633A8 (en) | 7-[2-[4- (6-fluoro-3-methyl -1,2-benzisoxazol-5-yl) -1-piperazinyl]ethyl] -2- ( 1-propynyl) -7h-pyrazolo- [ 4,3-e]-[1,2,4] -triazolo- [1,5-c] -pyrimidin- 5 amine | |
EA200600480A1 (ru) | Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |